ArticleThe Journal of clinical and aesthetic dermatology2025
Durability of Conventional Immunosuppressants in the Treatment of Oral Lichen Planus.
Article in The Journal of clinical and aesthetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral lichen planus and apremilast: Case series and literature review.JAAD case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral lichen planus (OLP) is an inflammatory disease involving the oral mucosa. It affects roughly 0.5% to 2% of the global population and has an associated risk of oral squamous cell carcinoma. Treatment of moderate to severe OLP often requires immunosuppression. The durability of immunosuppressive medication is currently unknown and is important for understanding therapeutic testing needs.
objectiveWe investigated traditional immunosuppressive drug survival in patients with OLP and evaluated potential discontinuation factors.
methodsWe retrospectively analyzed patients with OLP treated with methotrexate, mycophenolate, azathioprine, or cyclosporine. Time to medication discontinuation was evaluated using the Kaplan-Meier estimator, and Cox proportional hazards regression was used to compare the risk of discontinuing a medication between medications and across patient demographic and disease factors.
resultsWe identified 125 treatment periods with mycophenolate (n=58), methotrexate (n=34), azathioprine (n=19), or cyclosporine (n=14). Most patients had erosive disease (92%), and median time (IQR) to discontinuation due to adverse events or inefficacy was 9.43 months (6.51-16.1). Overall, only cyclosporine was associated with higher risk of discontinuation compared to methotrexate (hazard ratio [HR]: 2.94; 95% confidence interval [CI]: 1.32-6.45). There was no evidence for risk differences across age or sex for the overall cohort. Within individual medication groups, age was associated with a small increased risk of discontinuing mycophenolate (HR: 1.05; 95% CI: 1.00-1.10) and a small decreased risk in cyclosporine (HR=0.94, 95% CI: 0.89-0.99). Otherwise, no demographic factors were associated with discontinuation. Treatment success was reported 8 times. DISCUSSION: Immunosuppressive medications were frequently discontinued after short time periods, and few were discontinued due to success. These data highlight the need for better systemic therapy in OLP.
Indexed as
Identifiers
41647764PMC12871496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.